Allakos Inc Results From Phase 1 Study Of Subcutaneously Administered Lirentelimab (AK002) Call Transcript
Greetings. Welcome to Allakos Lirentelimab Subcutaneous and Prevalence Study Results Conference Call. (Operator Instructions) Please note this conference is being recorded.
I will now turn the conference over to your host, CEO, Robert Alexander. You may begin.
Okay. Well, thank you, and I'd like to thank everybody for joining the call. Alan, can you key ahead one slide. So just a reminder that I will be making forward-looking statements, so please refer to our SEC filings for a description of our risk factors. Agenda.
Okay. So in terms of what we'll go through today, we -- I'll give a brief overview, and then Henrik will show the subcutaneous data, followed by Amol Kamboj, who's going through our prevalence results. And then we'll have 2 key opinion leaders join us to put the prevalence data in a broader context. And then we'll follow-up with Henrik giving an update on the current clinical plans, and then we'll go to Q&A.
Okay. So today's -- I think as everybody knows, today's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
